treatment of extensive stage small cell lung cancer (ES-SCLC)!
Treatment of specific non-small cell lung cancer patients Merck MET inhibitors in Germany was reviewed by the FDA as a priority.
New treatment for triple negative breast cancer - GLUT1 inhibitor.
The state supports the social management of medical treatment in the United States, Maotai into the field of medical care.
With the reform of outpatient reimbursement system, the drug treatment structure is facing great adjustment.
New medicine for rare diseases! Novart's first supplement factor B inhibitor LNP023 treatment
Eye performance for the treatment of cysteine deposition FDA approved the first cysteine eye drops.
The clinical application for the treatment of R/R ENKTL by cornerstone pharmaceutical company PD-L1 antibody is approved by fda review in the United States.
"Reduce damage and strengthen repair"! The treatment of multiple sclerosis (RMS) in the treatment of Peposia has long-term efficacy and safety!
Bayer chlorinated radon (223Ra) injections in China have been approved for the treatment of prostate cancer.
New migraine medicine! Lingbei CGRP targeted antibody Vyepti during migraine attack preventive treatment PHASE III study was successful!
of the list of expert committees on the diagnosis, treatment and protection of rare diseases of the National Health and Health Commission.
Missed the main destination hundreds of mesquite treasure Idhifa combination therapy treatment leukemia trial failed.
Dietary treatment of phenylalanine uremia and low phenylalanine.
Innovative treatments for gastrointestinal cancer! Bronger Ingham pioneered RAILR2/CDH17 dual-specific antibody BI 905711 into human clinical trials!
Rare pediatric epilepsy new drug! Fintepla (Finteplamin) Treatment of Dravet Syndrome Phase 3 Phase
Breakthrough drugs for cystic fibrosis (CF)! Vertex's innovative triple therapy Trikafta treatment
by the FDA Breakthrough Therapy: Treatment of Nasopharyngeal Cancer!
The innovative HBsAg inhibitor GST-HG121 for hepatitis B treatment in Guangshengtang was approved clinically.
2020 EASL: Early results of the treatment of hepatitis B virus infection by Asheng Pharmaceutical IAP inhibitors were released.